1228652-22-9Relevant academic research and scientific papers
Discovery of a 4-Azetidinyl-1-thiazoyl-cyclohexane CCR2 antagonist as a development candidate
Zhang, Xuqing,Hou, Cuifen,Hufnagel, Heather,Singer, Monica,Opas, Evan,McKenney, Sandra,Johnson, Dana,Sui, Zhihua
, p. 1039 - 1044 (2013/02/23)
We have discovered a novel series of 4-Azetidinyl-1-Aryl-cyclohexanes as CCR2 antagonists. Divergent SAR studies on hCCR2 and hERG activities led to the discovery of compound 8d, which displayed good hCCR2 binding affinity (IC 50, 37 nM) and po
CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2
-
Page/Page column 146, (2012/01/06)
The present invention comprises compounds of Formula (I). Wherein: R1, R2, R4, J, Q, and A are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).
4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2
-
Page/Page column 27, (2010/06/19)
The present invention comprises compounds of Formula (I). wherein: R1, R2, R3, and R4 are as defined in the specification. The invention also comprises pharmaceutical compositions comprising the compounds of formula (I) and methods of preventing, treating or ameliorating a CCR2 mediated syndrome, disorder or disease, for example, type II diabetes, obesity or asthma, by administering the compounds of formula (I).
